

DR. MED. BRITTA GALLING, MA**Education and practical experience**

11/2016 – now	Consultant and Researcher Department of Child and Adolescent Psychiatry Charité University Medical Center Augustenburger Platz 1 13353 Berlin (Germany)
04/2016 – now	Assistant Professor of Psychiatry Hofstra Northwell School of Medicine Hempstead, New York (US)
07/2016	Psychiatric Consultant I Specialist Child- and Adolescent Psychiatry Medical Chamber of Hamburg (Germany)
04/2014 – 10/2016	Post-doctoral research fellow Feinstein Institute for Medical Research The Zucker Hillside Hospital Division of Psychiatry Research 75-59 263rd Street Glen Oaks, NY 11004 (US)
11/2012	Doctor of Medicine (Dr. med.), Prof. D. Naber University of Hamburg (Germany)
04/2011 – 12/2013	Child and General Psychiatry Residency University Medical Center Hamburg-Eppendorf Martinistr. 52 20246 Hamburg (Germany)
01/2011	Master`s Degree Social Anthropology (M.A.), Prof. M. Schnegg University of Hamburg (Germany)
04/2010 – 03/2011	Psychosomatic Residency Heinrich-Heine-Klinik Am Stinthorn 42 14476 Potsdam (Germany)
07/2009	Medical State Exam (M.D.)
10/2004 – 04/2010	Studies of Social Anthropology University of Hamburg (Germany)
10/2002 – 04/2009	Studies of Medicine University of Hamburg (Germany) Université de Bordeaux (France) McGill University (Kanada) The University of Melbourne (Australia)

Additional qualifications

05/2011	Study Doctor (Certificate for Study Doctors according to pharmaceutical legislation, University Medical Center Hamburg-Eppendorf)
10/2013	Graduation, advanced training program for psychotherapy, Institute for Cognitive Behavioral Therapy, Lübben (Germany)
05/2017	Study Doctor (Certificate for Study Doctors according to pharmaceutical legislation, Charité Universitätsmedizin)

Research projects

10/2017 – now	TDM-VIGIL (Therapeutic Drug Monitoring) Charité University Medical Center, Berlin (Germany) Position: On-site Principal Investigator (Main PI: Karin Egberts, Paul Plener)
11/2016 – now	B*EASY (Berlin - Early Psychosis and Substance Use in Youth) Charité University Medical Center, Berlin (Germany) Position: Principal Investigator FACT (Fluoxetine-Aripiprazole-Comparative Trial) Charité University Medical Center, Berlin (Germany) Position: Principal Investigator
04/2014-10/2016	AMDPS (Adolescent Mood Disorder and Psychosis Study) The Zucker Hillside Hospital, Glen Oaks, NY (US) Position: Co-Principal Investigator (PI: Christoph U. Correll) MC4R (1/2-MC4R Genotype and Pediatric Antipsychotic Drug-Induced Weight Gain) The Zucker Hillside Hospital, Glen Oaks, NY (US) Position: Co-Principal Investigator (PI: Christoph U. Correll) 0092 – Biological and genetic risk factors for weight gain and metabolic abnormalities in children and adolescents with psychotic and aggressive disorder The Zucker Hillside Hospital, Glen Oaks, NY (US) Position: Co-Principal Investigator (PI: Christoph U. Correll) RAAPP (The Role of Antipsychotics and Antidepressants in Preventing Psychosis) The Zucker Hillside Hospital, Glen Oaks, NY (US) Position: Co-Principal Investigator (PI: Christoph U. Correll)

05/2011-12/2013	ACCESS III (ICEP: Integrated Care for Early Psychosis University Medical Center Hamburg-Eppendorf Position: Study doctor (PI: Martin Lambert)
11/2007-04/2009	The influence of music on the attention of first episode patients with schizophrenia University Medical Center Hamburg-Eppendorf Position: Doctoral student (PI: Christian Huber)

Grants

01/2017 – 12/2018	NARSAD Young Investigators Grant, Brain and Behavior Foundation, \$70.000
04/2016 – 09/2016	DFG Return Grant, \$12 000
04/2014 – 03/2016	DFG Research Grant, German Research Foundation, \$100 000
02/2001 – 02/2002	Educational Provision for gifted youth (Rhineland-Palatinate), \$5 000

Awards

04/2018	ECNP School auf Child & Adolescent Neuropsychopharmacology Fellowship, European College of Clinical Neuropsychopharmacology
03/2018	EPA Scholarship Award, European Psychiatric Association
07/2017	ESCAP International Research Academy Awardee, European Society for Child and Adolescent Psychiatry
05/2017	International Training Seminar in Child & Adolescent Psychiatry Fellowship, Child Foundation
05/2017	ASCP Mentor, American Society of Clinical Psychopharmacology
09/2016	ECNP Travel Award, European College of Neuropsychopharmacology
05/2016	ASCP New Investigators Award, American Society of Clinical Psychopharmacology
07/2015	ESCAP International Research Academy Awardee, European Society for Child and Adolescent Psychiatry
01/2015	ASCP Clinical Trials in Psychopharmacology Workshop Fellowship, American Society of Clinical Psychopharmacology
02/2002	Rudolph-Center Price for outstanding performance at school

Reviewer/ Editorial Board

European Archives of Psychiatry and Clinical Neurosciences, Medicine, Progress in
Neuropsychopharmacology, Neuropsychopharmacology, JAMA Pediatrics, Journal of Psychiatry
Research, European Psychiatry, European Journal of Endocrinology

Journals (peer reviewed)

Galling B, Vernon A, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, Tsoy-Podosenin M, Poyurovsky M, Kane JM, Correll CU. Efficacy and Safety of Antidepressant Augmentation of Continued Antipsychotic Treatment in Patients with Schizophrenia. *Acta Psychiatr Scand*. 2018 (in print) [**IMPACT FACTOR: 5.605**]

Correll CU, **Galling B**. Polypharmacy in Youth Treated With Antipsychotics: Do Antidepressants or Stimulants Add to the Risk for Type 2 Diabetes? *J Am Acad Child Adolesc Psychiatry*. 2017 Aug;56(8):634-635. [**IMPACT FACTOR: 7.260**]

Lambert M, Schöttle D, Ruppelt F, Rohenkohl A, Sengutta M, Luedecke D, Nawara LA, **Galling B**, Falk AL, Wittmann L, Niehaus V, Sarikaya G, Rietschel L, Gagern C, Schulte-Markwort M, Unger HP, Ott S, Romer G, Daubmann A, Wegscheider K, Correll CU, Schimmelmann BG, Wiedemann K, Bock T, Gallinat J, Karow A. Early detection and integrated care for adolescents and young adults with psychotic disorders: the ACCESS III study. *Acta Psychiatr Scand*. 2017 Jun 6 [**IMPACT FACTOR: 5.605**]

Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. *World Psychiatry*. 2017 Feb;16(1):77-89 [**IMPACT FACTOR: 20.205**]

Cervesi C, Park SY, **Galling B**, Molteni S, Masi G, Gerhard T, Olfson M, Correll CU. Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders: Results of a Meta-Analysis and Meta-Regression Analyses. *J Clin Psychiatry*. 2017 Jan 3 [**IMPACT FACTOR: 5.498**]

Lambert M, Schöttle D, Sengutta M, Ruppelt F, Rohenkohl A, Luedecke D, Nawara LA, **Galling B**, Falk AL, Wittmann L, Niehaus V, Sarikaya G, Handwerk U, Rothländer W, Rietschel L, Gagern C, Lange B, Meigel-Schleiff C, Naber D, Schulte-Markwort M, Krüger H, Unger HP, Sippel S, Ott S, Romer G, Daubmann A, Wegscheider K, Correll CU, Schimmelmann BG, Bock T, Gallinat J, Karow A. Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (ACCESS III). *Early Interv Psychiatry*. 2016 Sep 12. [**IMPACT FACTOR: 2.889**]

Vancampfort D, Correll CU, **Galling B**, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. *World Psychiatry*. 2016 Jun;15(2):166-174 [**IMPACT FACTOR: 20.205**]

Park SY, Cervesi C, **Galling B**, Molteni S, Walyzada F, Ameis SH, Gerhard T, Olfson M, Correll CU. Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A

Meta-Analysis. *J Am Acad Child Adolesc Psychiatry*. 2016 Jun;55(6):456-468. **[IMPACT FACTOR: 7.260]**

Galling B*, Roldán A*, Rietschel L, Hagi K, Walyzada F, Zheng W, Cao XL, Xiang YT, Kane JM, Correll CU. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. *Expert Opin Drug Saf*. 2016 May;15(5):591-612 **[IMPACT FACTOR: 2.911]**

Molteni S, Carbon M, Lops J, Soto EC, Cervesi C, Sheridan EM, **Galling B**, Saito E, Krakower S, Dicker R, Foley C, Fornari V, Balottin U, Correll CU. Correlates of Subjective Caregiver Strain in Caregivers of Youth Evaluated in a Pediatric Psychiatric Emergency Room. *J Child Adolesc Psychopharmacol*. 2016 Mar 15. **[IMPACT FACTOR: 2.149]**

Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Kane JM, Stubbs B, Vancampfort D, De Hert M, Olfson M, Kahl KG, Martin A, Guo J, Lane HY, Sung FC, Liao CH, Arango C, Correll CU (2015). Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2016 Mar 1;73(3):247-59. **[IMPACT FACTOR: 14.417]**

Galling B, Calsina Ferrer A, Abi Zeid Daou M, Sangroula D, Hagi K, Correll CU. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. *Expert Opin Drug Saf*. 2015 Sep 10:1-22. **[IMPACT FACTOR: 2.911]**

Galling B, Garcia MA, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. *Expert Opin Drug Saf*. 2015 Aug;14(8):1181-99. **[IMPACT FACTOR: 2.911]**

Lambert M, Schöttle D, Sengutta M, Lüdecke D, Nawara AL, **Galling B**, Handwerk U, Rothländer W, Falk AL, Rietschel L, Gagern C, Sarikaya G, Wittmann L, Ruppelt F, Daubmann A, Lange B, Naber D, Schulte-Markwort M, Unger HP, Ott S, Romer G, Krüger H, Gallinat J, Wegscheider K, Bock T, Karow A. [Early Detection and Integrated Care in Adolescents and Young Adults with Severe Psychotic Illnesses]. *Psychiatr Prax*. 2015 Jul;42 Suppl 1:S49-53. **[IMPACT FACTOR: 0.180]**

Galling B, Correll CU. Do antipsychotics increase diabetes risk in children and adolescents? *Expert Opin Drug Saf*. 2015 Feb; 14(2):219-41. **[IMPACT FACTOR: 2.911]**

Hauser M, **Galling B**, Correll CU. Suicidal ideation and suicide attempts in children and adolescents with bipolar disorder: a systematic review of prevalence and incidence rates, correlates, and targeted interventions. *Bipolar Disorders*. 2013 Aug;15(5):507-23 **[IMPACT FACTOR: 4.965]**

Books and book chapters

Galling B, Rietschel L. Nonadherence and service disengagement in schizophrenia. In: Lambert M., Naber D. (eds.) *Current Schizophrenia*. Current Medicine Group (CMG). 2011, 3rd ed.

Galling B, Rietschel L. The most recommended psychosocial interventions in schizophrenia. In: Lambert M, Naber D (eds.) Current Schizophrenia. Current Medicine Group (CMG). 2011, 3rd ed.

Rietschel L, **Galling B**, Lambert M. Adherence to treatment and doctor-patient-relationship in the therapy of schizophrenia [Therapieadhärenz und Arzt-Patienten-Beziehung in der Schizophreniebehandlung]. In: Wolf K, Lambert M, Peters S. Emotionale Kompetenz bei Schizophrenie, Georg-Thieme-Verlag, Stuttgart, 2011

Conference contributions

Galling B, Correll. Effectiveness of coordinated specialty care for patients with early psychosis: Systematic review, meta-analysis and metaregression-analysis. WPA, Berlin (8-12/10/2017)

Galling B, Correll. Antipsychotic augmentation in schizophrenia: results from a systematic review and meta-analysis. WPA, Berlin (8-12/10/2017)

Galling B, Correll CU. Antidepressant augmentation of antipsychotics in schizophrenia: Results of a Systematic review, meta-analysis and metaregression analysis. ECNP, Paris (2-5/9/2017)

Galling B. Effectiveness of Early Intervention Services for Patients with Early Psychosis, ESCAP Conference, Genève (9-11/7/2017)

Galling B. Early Recognition and treatment strategies for youth with Psychosis [Innovative Versorgungskonzepte zur Früherkennung und Behandlung junger Psychoseerkrankter]. Kolloquium Kinder- und Jugendpsychiatrie, Universitätsmedizin, Berlin (21/6/2017)

Galling B. Early Recognition and treatment strategies for youth with Psychosis [Früherkennung und Behandlung von Psychosen]. Walstedde (16/9/2017)

Galling B, Correll CU. Antidepressant augmentation and co-initiation treatment in acute major depressive disorder: A systematic review, meta-analysis and metaregression analysis. ASCP, Miami (29/5-3/6/2017)

Sangroula D, **Galling B**, Calsina Ferrer A., Correll CU. Antidepressant augmentation and co-initiation treatment in acute major depressive disorder: A Systematic Review, Meta-regression, and Meta-analysis. Annual Meeting American Psychiatric Association, San Diego (20-24/5/2017)

Galling B, Sangroula D, Calsina Ferrer A., Correll CU. Antidepressant augmentation and co-initiation treatment in acute major depressive disorder: A Systematic Review, Meta-regression, and Meta-analysis. Annual Meeting American Psychiatric Association, San Diego (20-24/5/2017)

Galling B. Early Recognition and treatment strategies for youth with Psychosis [Innovative Versorgungskonzepte zur Früherkennung und Behandlung junger Psychoseerkrankter]. University Münster (4/2/2017)

Galling B, Correll CU. Antidepressant augmentation and co-initiation treatment in major depressive disorder: Systematic review, meta-analysis and metaregression analysis. DGPPN, Berlin (23-26/11/2016)

Galling B, Sangroula D, Calsina Ferrer A, Correll CU. Antidepressant augmentation and co-initiation treatment in acute major depressive disorder: A systematic review, meta-analysis and metaregression analysis. ECNP, Vienna (17-20/9/2016)

Guinart D, **Galling B**, Sangroula D, Calsina Ferrer A, Correll CU. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. ECNP, Vienna (17-20/9/2016)

Roldán A, **Galling B**, Correll CU. Antipsychotic Co-Initiation vs Monotherapy in Schizophrenia – A systematic review, meta-analysis and metaregression analysis. ECNP, Vienna (17-20/9/2016)

Galling B, Roldán A, Kane J, Correll CU. Efficacy and Safety of Antipsychotic Augmentation versus Antipsychotic Monotherapy in Schizophrenia. Results from a Systematic Review and Metaanalysis. ASCP Annual Meeting, Scottsdale (30/5-3/6/2016)

Leineweber D, **Galling B**, Schürmeyer TH. Autoimmune thyroid diseases (AITD) and mental illness: An evaluation of parietal cell antibodies, intrinsic factor antibodies, vitamin B12 and psychiatric symptoms in patients with AITD and Non-AITD controls. European Congress of Endocrinology, Munich (28-31/5/2016)

Correll CU, **Galling B**. Effectiveness of Early Intervention Services for Patients with Early Psychosis: Systematic Review and Meta-analysis of Specialized Care versus Usual or Modular Care. SIRS Conference, Florence (2-6/4/2016)

Correll CU, **Galling B**. Psychopharmacological polypharmacy in severe mental illness: New data on efficacy and safety [Psychopharmakologische Kombinationstherapien bei schweren psychischen Erkrankungen: neue Daten zu Effektivität und Sicherheit] DGPPN Kongress, Berlin (25-28/11/2015)

Roldán A, **Galling B**, Correll CU. Are antipsychotics a risk factor for type 2 diabetes in youth? A meta-analysis of incidence rates compared to healthy and psychiatric controls. ECNP Conference, Amsterdam (12-16/9/2015)

Galling B, Roldán A, Walyzada F, Correll CU. Antipsychotic polypharmacy in schizophrenia: results from a systematic review and meta-analysis of augmentation. ECNP Conference, Amsterdam (12-16/9/2015)

Garcia M, **Galling B**, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer cotreatment in acute bipolar disorder: A systematic review and exploratory metaanalysis. ECNP Conference, Amsterdam (12-16/9/2015)

Galling B, Correll CU. Antipsychotic treatment and diabetes in youth. ESCAP Conference, Madrid (20-24/6/2015)

Galling B. Antipsychotic treatment and diabetes in youth. Grand Round, Nassau Country Hospital, School of Medicine, Stony Brooke University (14/5/2015)

Galling B, Correll CU. Diagnostic process and symptomatic course in youth at risk for Psychosis [Diagnostische und Symptomatische Verläufe bei Jugendlichen mit einem Risikosyndrom für eine Psychose] DGKJP Kongress, Munich (4-7/3/2015)

Galling B, Correll CU. Is antipsychotic therapy a risk factor for the development of type-2-diabetes? [Ist Antipsychotika-Therapie ein Risikofaktor für Typ-2-Diabetes-Entwicklung bei Kindern und Jugendlichen?] DGKJP Kongress, Munich (4-7/3/2015)

Galling B. Psychosis in Kuala Lumpur – disease concepts and stigmatization in the context of traditional and western medicine. In: Southeast Asian concepts and approaches of health and healthcare. EuroSEAS Conference, Lisbon (2-5/7/2013)

Galling B, Sauerbier AL, Karow A, Schoettle D, Gagern C, Glisman S, Romer G, Bock T, Lambert M. Psychosis health network: Early recognition and integrated care of first episode youth – the Hamburg model (Integrative Care in Early Psychosis) [Gesundheitsnetz Psychose: Früherkennung und Integrierte Versorgung von ersterkrankten Jugendlichen und jungen Erwachsenen nach dem Hamburger Modell] (Integrative Care in Early Psychosis). DGPPN-Kongress, Berlin (27-30/11/2013)

Galling B, Krause H Rietschel L, Banneck G, Huber C, Stegemann T, Lambert M. The influence of music on the attention in first episode patients with schizophrenia [Der Einfluss von Musik auf die Aufmerksamkeit bei Ersterkrankten Patienten mit Schizophrenie], DGPPN-Kongress, Berlin (27-30/11/2013)

Galling B. Lambert M, Karow A, Gagern C, Sauerbier AL, Gaska P, Schöttle D, Rietschel L, Romer G. Integrative Care for Early Psychosis (ICEP): Improved Early Recognition and Intervention in the early phase of psychotic illness [Integrative Care for Early Psychosis (ICEP): Verbesserte Früherkennung und -behandlung in der frühen Krankheitsphase einer psychotischen Erkrankung], DGKJP Kongress, Rostock (6-9/3/2013)

Lambert M, Karow A, Bock T, Rietschel L, Gagern C, Schöttle D, **Galling B**, Romer G, Schulte-Markwort M, Naber D. The Psychosis Early recognition and treatment project at the university hospital Hamburg-ependorf [Das „Psychosen Ersterkennungs- und Behandlungsprojekt“ (PEB) am UK Hamburg-Eppendorf], DGPPN-Kongress, Berlin (21-24/11/2012)

Karow A, Schöttle D, **Galling B**, Kerstan A, Sauerbier AL, Gagern C, Naber D, Bock T, Lambert M (2012) The modell for integrative care „Psychosis health network2: rationale and treatment model [Das Integrierte Versorgungsmodell „Gesundheitsnetz Psychose“: Rationales und Behandlungsmodell], DGPPN-Kongress, Berlin (21-24/11/2012)

Galling B, Lambert M, Karow A, Bock T, Meister K, Rietschel L, Mudra S, Kiel W, König HH, Unger HP, Romer G. Psychosis health network: Improved early recognition and intervention in the early phase of psychosis [Gesundheitsnetz Psychose: Verbesserte Früherkennung und -behandlung in der frühen Krankheitsphase einer psychotischen Erkrankung], 4th scientific meeting for psychotherapy research in children and adolescents [4. Wissenschaftliche Tagung für Psychotherapieforschung im Kindes- und Jugendalter], Marburg (29-30/9/2011)

Lambert M, Karow A, Bock T, Schöttle D, Ohm G, Romer G, Hoffmann S, **Galling B**, Meister K, Rietschel L, Naber D. Early recognition of psychosis – the psychosis health network [Früherkennung

von Psychosen im jungen Erwachsenenalter – das Gesundheitsnetz Psychose], DGPPN-Kongress, Berlin (15-18/11/2011)

Galling B, Albrecht NJ. (2010) Satisfaction of migrants in inpatient treatment [Zufriedenheit von Migrantinnen und Migranten in der stationären Versorgung], German-Turkish Psychiatry Congress [Deutsch-Türkischer Psychiatriekongress], Berlin (21-25/9/2010)